Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

28 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Andersen S, et al. Among authors: hansen bv. Kidney Int. 2000 Feb;57(2):601-6. doi: 10.1046/j.1523-1755.2000.00880.x. Kidney Int. 2000. PMID: 10652037 Clinical Trial.
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, Vaag AA. Lund SS, et al. Among authors: hansen bv. BMJ. 2009 Nov 9;339:b4324. doi: 10.1136/bmj.b4324. BMJ. 2009. PMID: 19900993 Free PMC article. Clinical Trial.
Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH. Astrup AS, et al. Among authors: hansen bv. Diabetes Care. 2006 Feb;29(2):334-9. doi: 10.2337/diacare.29.02.06.dc05-1242. Diabetes Care. 2006. PMID: 16443883
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Jacobsen P, et al. Among authors: hansen bv. Nephrol Dial Transplant. 2002 Jun;17(6):1019-24. doi: 10.1093/ndt/17.6.1019. Nephrol Dial Transplant. 2002. PMID: 12032191 Clinical Trial.
Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH. Rossing K, et al. Among authors: hansen bv. Diabetes Care. 2003 Jan;26(1):150-5. doi: 10.2337/diacare.26.1.150. Diabetes Care. 2003. PMID: 12502672 Clinical Trial.
Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy.
Tarnow L, Stehouwer CD, Emeis JJ, Poirier O, Cambien F, Hansen BV, Parving HH. Tarnow L, et al. Among authors: hansen bv. Nephrol Dial Transplant. 2000 May;15(5):625-30. doi: 10.1093/ndt/15.5.625. Nephrol Dial Transplant. 2000. PMID: 10809802
Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes.
Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Tarnow L, et al. Among authors: hansen bv. Diabetologia. 2006 Oct;49(10):2256-62. doi: 10.1007/s00125-006-0359-4. Epub 2006 Aug 26. Diabetologia. 2006. PMID: 16937127
Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy.
Tarnow L, Hildebrandt P, Hansen BV, Borch-Johnsen K, Parving HH. Tarnow L, et al. Among authors: hansen bv. Diabetologia. 2005 Jan;48(1):149-55. doi: 10.1007/s00125-004-1595-0. Epub 2004 Dec 23. Diabetologia. 2005. PMID: 15616804
Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients.
Lajer M, Tarnow L, Fleckner J, Hansen BV, Edwards DG, Parving HH, Boel E. Lajer M, et al. Among authors: hansen bv. Diabet Med. 2004 Aug;21(8):867-73. doi: 10.1111/j.1464-5491.2004.01259.x. Diabet Med. 2004. PMID: 15270790
Effect of short-term hyperglycaemia on haemodynamics in type 1 diabetic patients.
Jacobsen P, Rossing K, Hansen BV, Bie P, Vaag A, Parving HH. Jacobsen P, et al. Among authors: hansen bv. J Intern Med. 2003 Nov;254(5):464-71. doi: 10.1046/j.1365-2796.2003.01216.x. J Intern Med. 2003. PMID: 14535968 Free article. Clinical Trial.
28 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback